RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Coinbase Earnings: Weak Cryptocurrency Prices Lead to Lower Trading Volume and Net Losses - Clone
We’ve lowered our fair value estimate of Coinbase stock.
stocks
Higher dividend for ASX member of our income pick list
Management lifted guidance and full-year dividend.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 22.30 | -0.24% |
| CAC 40 | 8,361.46 | 44.96 | 0.54% |
| DAX 40 | 24,998.40 | 197.49 | 0.80% |
| Dow JONES (US) | 49,595.67 | 94.74 | 0.19% |
| FTSE 100 | 10,556.17 | 82.48 | 0.79% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,637.29 | 90.62 | 0.40% |
| Nikkei 225 | 56,566.49 | 239.92 | -0.42% |
| NZX 50 Index | 13,031.62 | 86.29 | -0.66% |
| S&P 500 | 6,856.40 | 20.23 | 0.30% |
| S&P/ASX 200 | 8,958.90 | 20.40 | -0.23% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |